1
|
Hirose K, Sato M, Ichise K, Aoki M. Dose Rate Effect on Cell Survival in BNCT. Curr Issues Mol Biol 2023; 45:6986-6994. [PMID: 37754225 PMCID: PMC10530115 DOI: 10.3390/cimb45090441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 08/16/2023] [Accepted: 08/21/2023] [Indexed: 09/28/2023] Open
Abstract
The output constancy of the accelerator used for boron neutron capture therapy (BNCT) is essential to ensuring anti-tumor efficacy and safety. BNCT as currently practiced requires a wide variety of beam quality assessments to ensure that RBE dose errors are maintained within 5%. However, the necessity of maintaining a constant beam dose rate has not been fully discussed. We therefore clarified the effect of different physical dose rates of the accelerator BNCT on biological effects. SAS and A172 cells exposed to 10B-boronophenylalanine were irradiated using a neutron beam (normal operating current, 100 μA) at the Aomori Quantum Science Center. Thermal neutron flux was attenuated to 50.0 ± 0.96% under 50 μA irradiation compared to that under 100 μA irradiation. Cells were given physical doses of 1.67 and 3.36 Gy at 30 and 60 mC, respectively, and survival was significantly increased after 50 μA irradiation for both cell types (p = 0.0052 for SAS; p = 0.046 for A172, for 60 mC). Differences in accelerator BNCT beam dose rates have non-negligible effects on biological effects. Dose rate fluctuations and differences should not be easily permitted to obtain consistent biological effects.
Collapse
Affiliation(s)
- Katsumi Hirose
- Department of Radiation Oncology, Graduate School of Medicine, Hirosaki University, 5 Zaifu-cho, Hirosaki 036-8562, Japan; (M.S.); (K.I.); (M.A.)
- Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama 963-8052, Japan
| | - Mariko Sato
- Department of Radiation Oncology, Graduate School of Medicine, Hirosaki University, 5 Zaifu-cho, Hirosaki 036-8562, Japan; (M.S.); (K.I.); (M.A.)
- Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama 963-8052, Japan
| | - Koji Ichise
- Department of Radiation Oncology, Graduate School of Medicine, Hirosaki University, 5 Zaifu-cho, Hirosaki 036-8562, Japan; (M.S.); (K.I.); (M.A.)
- Osaka Heavy-Ion Therapy Center, 3-1-10 Otemae, Chuo-ku, Osaka 540-0008, Japan
| | - Masahiko Aoki
- Department of Radiation Oncology, Graduate School of Medicine, Hirosaki University, 5 Zaifu-cho, Hirosaki 036-8562, Japan; (M.S.); (K.I.); (M.A.)
| |
Collapse
|
2
|
Komori S, Hirose K, Sato M, Takeuchi A, Kato R, Motoyanagi T, Harada T, Yamazaki Y, Harada M, Narita Y, Kato T, Takai Y. Dosimetric effect of set-up error in accelerator-based boron neutron capture therapy for head and neck cancer. JOURNAL OF RADIATION RESEARCH 2022; 63:684-695. [PMID: 35482434 PMCID: PMC9303597 DOI: 10.1093/jrr/rrac017] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 01/31/2022] [Indexed: 05/12/2023]
Abstract
The dosimetric effect of set-up error in boron neutron capture therapy (BNCT) for head and neck cancer remains unclear. In this study, we analyzed the tendency of dose error by treatment location when simulating the set-up error of patients. We also determined the tolerance level of the set-up error in BNCT for head and neck cancer. As a method, the distal direction was shifted with an interval of 2.5 mm, from 0.0 mm to +20.0 mm and compared with the dose at the reference position. Similarly, the horizontal direction and vertical direction were shifted, with an interval of 5.0 mm, from -20.0 mm to +20.0 mm. In addition, cases with 3.0 mm and 5.0 mm simultaneous shifts in all directions were analyzed as the worst-case scenario. The dose metrics of the minimum dose of the tumor and the maximum dose of the mucosa were evaluated. From unidirectional set-up error analysis, in most cases, the set-up errors with dose errors within ±5% were Δdistal < +2.5 mm, Δhorizontal < ±5.0 mm and Δvertical < ±5.0 mm. In the simulation of 3.0 mm shifts in all directions, the errors in the minimum tumor dose and maximum mucosal dose were -3.6% ±1.4% (range, -5.4% to -0.6%) and 2% ±1.4% (range, 0.4% to 4.5%), respectively. From these results, if the set-up error was within ±3.0 mm in each direction, the dose errors of the tumor and mucosa could be suppressed within approximately ±5%, which is suggested as a tolerance level.
Collapse
Affiliation(s)
- Shinya Komori
- Corresponding author. Department of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan, ; Tel: +81-24-934-5330; Fax: +81-24-934-5423
| | - Katsumi Hirose
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan
- Department of Radiation Oncology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan
| | - Mariko Sato
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan
- Department of Radiation Oncology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan
| | - Akihiko Takeuchi
- Department of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan
| | - Ryohei Kato
- Department of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan
| | - Tomoaki Motoyanagi
- Department of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan
| | - Takaomi Harada
- Department of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan
| | - Yuhei Yamazaki
- Department of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan
| | - Mayumi Harada
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan
| | - Yuki Narita
- Department of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan
| | - Takahiro Kato
- Department of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan
- School of Health Sciences, Fukushima Medical University, 10-6 Sakaemachi, Fukushima, Fukushima, 960-8516, Japan
| | - Yoshihiro Takai
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan
| |
Collapse
|
3
|
Hirose K, Kato T, Harada T, Motoyanagi T, Tanaka H, Takeuchi A, Kato R, Komori S, Yamazaki Y, Arai K, Kadoya N, Sato M, Takai Y. Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system. JOURNAL OF RADIATION RESEARCH 2022; 63:620-635. [PMID: 35726375 PMCID: PMC9303606 DOI: 10.1093/jrr/rrac030] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Revised: 01/20/2021] [Indexed: 06/15/2023]
Abstract
The irradiation field of boron neutron capture therapy (BNCT) consists of multiple dose components including thermal, epithermal and fast neutron, and gamma. The objective of this work was to establish a methodology of dosimetric quality assurance (QA), using the most standard and reliable measurement methods, and to determine tolerance level for each QA measurement for a commercially available accelerator-based BNCT system. In order to establish a system of dosimetric QA suitable for BNCT, the following steps were taken. First, standard measurement points based on tissue-administered doses in BNCT for brain tumors were defined, and clinical tolerances of dosimetric QA measurements were derived from the contribution to total tissue relative biological effectiveness factor-weighted dose for each dose component. Next, a QA program was proposed based on TG-142 and TG-198, and confirmed that it could be assessed whether constancy of each dose component was assured within the limits of tolerances or not by measurements of the proposed QA program. Finally, the validity of the BNCT QA program as an evaluation system was confirmed in a demonstration experiment for long-term measurement over 1 year. These results offer an easy, reliable QA method that is clinically applicable with dosimetric validity for the mixed irradiation field of accelerator-based BNCT.
Collapse
Affiliation(s)
- Katsumi Hirose
- Corresponding author. Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, 963-8052 Japan, Tel: +81-24-934-5330,
| | - Takahiro Kato
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center and Southern Tohoku General Hospital, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
- Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 7-172 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
- School of Health Sciences, Fukushima Medical University, 10-6 Sakaemachi, Fukushima 960-8516, Japan
| | - Takaomi Harada
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center and Southern Tohoku General Hospital, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
| | - Tomoaki Motoyanagi
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center and Southern Tohoku General Hospital, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
| | - Hiroki Tanaka
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-nisi, Sennan-gun, Osaka 590-0494, Japan
| | - Akihiko Takeuchi
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center and Southern Tohoku General Hospital, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
| | - Ryohei Kato
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center and Southern Tohoku General Hospital, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
| | - Shinya Komori
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center and Southern Tohoku General Hospital, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
| | - Yuhei Yamazaki
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center and Southern Tohoku General Hospital, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
| | - Kazuhiro Arai
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center and Southern Tohoku General Hospital, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
- Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 7-172 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
| | - Noriyuki Kadoya
- Department of Radiation Oncology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan
| | - Mariko Sato
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center and Southern Tohoku General Hospital, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
- Department of Radiology and Radiation Oncology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Yoshihiro Takai
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center and Southern Tohoku General Hospital, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
| |
Collapse
|